메뉴 건너뛰기




Volumn 45, Issue 1, 2012, Pages 69-71

Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: A case report

Author keywords

Asthma; Omalizumab; Soluble FasL; T h1; T h2

Indexed keywords

BUDESONIDE; CHEMOKINE RECEPTOR CCL17; CHEMOKINE RECEPTOR CCL7; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; OMALIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 84862805293     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.12.026     Document Type: Article
Times cited : (2)

References (11)
  • 1
    • 63449107848 scopus 로고    scopus 로고
    • Anti-IgE therapy: clinical utility beyond asthma
    • Casale T.B., Stokes J. Anti-IgE therapy: clinical utility beyond asthma. J Allergy Clin Immunol 2009, 123:770-771.
    • (2009) J Allergy Clin Immunol , vol.123 , pp. 770-771
    • Casale, T.B.1    Stokes, J.2
  • 2
    • 0042530486 scopus 로고    scopus 로고
    • Allergic and nonallergic forms of atopic diseases
    • Novak N., Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003, 112:252-262.
    • (2003) J Allergy Clin Immunol , vol.112 , pp. 252-262
    • Novak, N.1    Bieber, T.2
  • 4
    • 70449106421 scopus 로고    scopus 로고
    • Effects of omalizumab on markers of inflammation in patients with allergic asthma
    • Holgate S., Smith N., Massanari M., Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009, 64:1728-1736.
    • (2009) Allergy , vol.64 , pp. 1728-1736
    • Holgate, S.1    Smith, N.2    Massanari, M.3    Jimenez, P.4
  • 5
    • 17744376022 scopus 로고    scopus 로고
    • Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy
    • Holgate S.T., Djukanović R., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35:408-416.
    • (2005) Clin Exp Allergy , vol.35 , pp. 408-416
    • Holgate, S.T.1    Djukanović, R.2    Casale, T.3    Bousquet, J.4
  • 6
    • 14844300188 scopus 로고    scopus 로고
    • The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
    • Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005, 115:459-465.
    • (2005) J Allergy Clin Immunol , vol.115 , pp. 459-465
    • Holgate, S.1    Casale, T.2    Wenzel, S.3    Bousquet, J.4    Deniz, Y.5    Reisner, C.6
  • 7
    • 67650938578 scopus 로고    scopus 로고
    • Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
    • Lowe P.J., Tannenbaum S., Gautier A., Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009, 68:61-76.
    • (2009) Br J Clin Pharmacol , vol.68 , pp. 61-76
    • Lowe, P.J.1    Tannenbaum, S.2    Gautier, A.3    Jimenez, P.4
  • 8
    • 58149113160 scopus 로고    scopus 로고
    • Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment
    • van Rensen E.L., Evertse C.E., van Schadewijk W.A., van Wijngaarden S., Ayre G., Mauad T., et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009, 64:72-80.
    • (2009) Allergy , vol.64 , pp. 72-80
    • van Rensen, E.L.1    Evertse, C.E.2    van Schadewijk, W.A.3    van Wijngaarden, S.4    Ayre, G.5    Mauad, T.6
  • 9
    • 4444232912 scopus 로고    scopus 로고
    • Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
    • Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170:583-593.
    • (2004) Am J Respir Crit Care Med , vol.170 , pp. 583-593
    • Djukanović, R.1    Wilson, S.J.2    Kraft, M.3    Jarjour, N.N.4    Steel, M.5    Chung, K.F.6
  • 10
    • 0038693651 scopus 로고    scopus 로고
    • Immunological changes in allergic asthmatics following treatment with omalizumab
    • Noga O., Hanf G., Kunkel G. Immunological changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003, 131:46-52.
    • (2003) Int Arch Allergy Immunol , vol.131 , pp. 46-52
    • Noga, O.1    Hanf, G.2    Kunkel, G.3
  • 11
    • 33646914451 scopus 로고    scopus 로고
    • Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma
    • Noga O., Hanf G., Brachmann I., Klucken A.C., Kleine-Tebbe J., Rosseau S., et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006, 117:1493-1499.
    • (2006) J Allergy Clin Immunol , vol.117 , pp. 1493-1499
    • Noga, O.1    Hanf, G.2    Brachmann, I.3    Klucken, A.C.4    Kleine-Tebbe, J.5    Rosseau, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.